Bioactive Materials-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2024-01-18 lyhjane 来自河北省

偏重的研究方向：生物材料
经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？

17 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2023-04-18 ms2000001636014343 来自江苏省

偏重的研究方向：生物材料
经验分享：请问大家通常投稿后多久拒稿or送审？

31 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2023-04-18 ms2000001636014343 来自江苏省

偏重的研究方向：生物医用高分子材料
经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？

25 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2023-01-16 不忘初心方为始终来自上海

偏重的研究方向：肿瘤和材料
经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！

178 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2021-11-02 wangzilk

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：动物应用;水凝胶
经验分享：21.08.26投稿
8.27 with editor
8.29 under review
9.10 Major revison
10.20 revison submitted to journal
10.21 under review
11.2 accept

516 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2022-10-25 1761f74021m

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：医学;生物材料
经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收

48 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2023-03-01 ms6000002069162134 来自四川省

1

41 0

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2021-08-24 wy-liang

人情刊

507 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2022-11-19 ms6000000227244670

关系户的后花园

132 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2182342, encodeId=355e218234241, content=偏重的研究方向：生物材料 经验分享：文章一般多长时间送审？2周多不送审是不是凶多吉少啦？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a17b62365, createdName=lyhjane, createdTime=Thu Jan 18 06:00:31 CST 2024, time=2024-01-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126915, encodeId=799e212691573, content=偏重的研究方向：生物材料 经验分享：请问大家通常投稿后多久拒稿or送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:22:55 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126913, encodeId=3bb82126913df, content=偏重的研究方向：生物医用高分子材料 经验分享：请问大家投稿后通常在主编手里待多久送审or拒稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29a28639913, createdName=ms2000001636014343, createdTime=Tue Apr 18 23:19:17 CST 2023, time=2023-04-18, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2110375, encodeId=8c8221103e563, content=偏重的研究方向：肿瘤和材料 经验分享：兄弟姐妹们，能预测一下2023年bioactive materials最终的影响因子么？能否超过20？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221024/94d4daccb86c4ca5b3c0bd72b3f07175/6ebb64a27cac4d6d816782ef7ba100b6.jpg, createdBy=f0842413356, createdName=不忘初心方为始终, createdTime=Mon Jan 16 00:59:15 CST 2023, time=2023-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1066274, encodeId=bf4f10662e46f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：动物应用;水凝胶 经验分享：21.08.26投稿 8.27 with editor 8.29 under review 9.10 Major revison 10.20 revison submitted to journal 10.21 under review 11.2 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Tue Nov 02 16:20:49 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095989, encodeId=87c1209598971, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：医学;生物材料 经验分享：之前投ACS NANO给了200多个审稿意见，修回后还是婉拒，然后投了这个。一审接近两个月，二审一个多月，审稿人给的评价很好，但是提的意见和问题很重要。好在回答让审稿人都比较满意，最后接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08932104609, createdName=1761f74021m, createdTime=Tue Oct 25 10:04:46 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117011, encodeId=ca8d211e011bd, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e998563453, createdName=ms6000002069162134, createdTime=Wed Mar 01 10:27:22 CST 2023, time=2023-03-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1010953, encodeId=59421010953e8, content=人情刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=507, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Aug 24 14:14:05 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101553, encodeId=080c210155317, content=关系户的后花园, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc95634150, createdName=ms6000000227244670, createdTime=Sat Nov 19 21:33:07 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056960, encodeId=ef1e1056960fd, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06815624073, createdName=ms2000001646317835, createdTime=Sat Oct 02 16:18:24 CST 2021, time=2021-10-02, status=1, ipAttribution=)]

2021-10-02 ms2000001646317835

审稿速度:2.0 | 投稿命中率:75.0
经验分享：21年7月下旬投稿的，有三个审稿人参与一审审稿，经历了2个月的审稿时间，三个审稿人评价都挺高，给了不少指导性的意见，没怎么刁难，主编给了大修，修回后4天接收

77 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务